Showing results (171-180 of 283) with videos related to

Sort By:
Pageof 29
European Journal of Biochemistry|February 15, 1984
Favism: a hemolytic disease associated with increased superoxide dismutase and decreased glutathione peroxidase activities in red blood cellsI Mavelli, M R Ciriolo, L Rossi, et al.
The Cancer Journal From Scientific American|February 11, 1998
Interleukin-2 therapy in relapsed acute myelogenous leukemiaG Meloni, M Vignetti, E Pogliani, et al.
Blood|October 1, 1996
Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)F Pane, F Frigeri, M Sindona, et al.
Bone Marrow Transplantation|November 1, 1994
Autologous bone marrow transplantation for childhood acute lymphoblastic leukemia in remission: first choice for isolated extramedullary relapse?P Colleselli, F Rossetti, C Messina, et al.
Nature Reviews. Neurology|March 30, 2022
Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuitsKerry J Ressler, Sabina Berretta, Vadim Y Bolshakov, et al.
Bone Marrow Transplantation|August 18, 2001
High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow TransplantationS Cesaro, G Meloni, C Messina, et al.
Annals of Hematology|April 27, 2002
Thrombotic thrombocytopenic purpura and pregnancy: a case report and a review of the literatureA Proia, R Paesano, F Torcia, et al.
Bone Marrow Transplantation|December 7, 2000
High-dose idarubicine, busulphan and melphalan as conditioning for autologous blood stem cell transplantation in multiple myeloma. A feasibility studyG Meloni, S Capria, S Trasarti, et al.
Bone Marrow Transplantation|August 1, 1994
European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Working Party on Acute Leukemia of the European Cooperative Group for Bone Marrow Transplantation (EMBT)F Mandelli, M Labopin, A Granena, et al.
The Journal of Pediatrics|August 1, 1995
Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis VaccineA Podda, G Bona, G Canciani, et al.
Pageof 29